Marrying Glucagon with GLP-1 to Treat Obesity
This article was originally published in Start Up
Executive Summary
Because glucagon raises blood glucose in the liver, it's counter-intuitive to think of it as the basis for a strategy to treat obesity and its associated consequences, including adult onset diabetes. But a research team has shown that a single-molecule "co-agonist" of glucagon and GLP-1 normalizes glucose tolerance and reduces body fat and weight in preclinical models. This molecular-level polypharmacy is particularly appealing in metabolic disease, where single mechanisms tend to offer only modest therapeutic effects.
You may also be interested in...
Clock Genes Influence Metabolism: A First Link With Glucose Production
It's common sense that Circadian rhythms manifest at the molecular level, given the obviously different metabolic functions while awake versus when asleep. Now, a group has shown that one of the body's "clock genes" helps regulate the production of new glucose in the liver. The findings could be applied to the discovery of novel treatments for type 2 diabetes and because the mechanism may also regulate signaling activities in other cell types, potentially alter the course of other diseases.
Altering The Insulin Resistance System
With the US deeply mired in an obesity epidemic, a growing aging population throughout the developed world, and rising rates of obesity, the market for therapeutic agents for metabolic disorders and especially type 2 diabetes will continue to grow. Little wonder that many emerging companies are pursuing innovative metabolic, obesity, and type 2 diabetes programs to supplement those of Big Pharma. We profile four of them in this issue: Catabasis Pharmaceuticals, Limerick BioPharma, Marcadia Biotech and Rhythm Pharmaceuticals.
Altering The Insulin Resistance System
With the US deeply mired in an obesity epidemic, a growing aging population throughout the developed world, and rising rates of obesity, the market for therapeutic agents for metabolic disorders and especially type 2 diabetes will continue to grow. Little wonder that many emerging companies are pursuing innovative metabolic, obesity, and type 2 diabetes programs to supplement those of Big Pharma. We profile four of them in this issue: Catabasis Pharmaceuticals, Limerick BioPharma, Marcadia Biotech and Rhythm Pharmaceuticals.